Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8857020 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL458623 | 1.00 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL22692162 | 0.88 | AKR1B1 (0.37) | LMNAL3MBTL1AKR1B1MPI | |
| SCHEMBL458800 | 0.84 | AKR1B1 (0.34) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL6521431 | 0.82 | LMNA (0.37) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL1428140 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL8970781 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL2318762 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL770242 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI | |
| SCHEMBL10713437 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1AKR1B1MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250161471-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | TIAN FENG (US) | 2025-05-22 | — | — | US | disclosed |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12227779-B2 | Modified DDAH polypeptides and their use to extracorporeally treat a patient's blood to reduce levels of ADMA | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-02-18 | — | — | US | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240391974-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES | AMBRX, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-20060183198-A1 | Methods for expression and purification of recombinant human growth hormone | AMBRX, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006073846-A2 | METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | AMBRX, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069220-A2 | MODIFIED HUMAN GROWTH HORMONE | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006069246-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | AMBRX, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009901-A2 | NOVEL ANTIGEN-BINDING POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | AMBRX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074524-A2 | MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | AMBRX, INC. (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | LMNA 2106/4885L3MBTL1 1261/4885TDP1 3768/4885 |
| US-20050220762-A1 | Modified human interferon polypeptides and their uses | IFNG, IFNAR1, EIF2AK2 | LMNA 3302/4885L3MBTL1 3467/4885TDP1 2199/4885 |
| US-12227779-B2 | Modified DDAH polypeptides and their use to extracorporeally treat a patient's blood to reduce levels of ADMA | ADM2, DDAH1, NPPA | LMNA 1068/4885L3MBTL1 292/4885TDP1 2230/4885 |
| US-20060183198-A1 | Methods for expression and purification of recombinant human growth hormone | GHITM, GHRHR, GHSR | LMNA 4784/4885L3MBTL1 2533/4885TDP1 3779/4885 |
| US-20250161471-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ERBB2, EGFR, ERBB3 | LMNA 4584/4885L3MBTL1 4228/4885TDP1 4199/4885 |
| US-20240391974-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES | IL2, IL2RA, IL15RA | LMNA 4669/4885L3MBTL1 1900/4885TDP1 4839/4885 |
| US-20060153860-A1 | Novel antigen-binding polypeptides and their uses | CD2BP2, CD74, LGALS3BP | LMNA 4499/4885L3MBTL1 2012/4885TDP1 2713/4885 |
| US-20060019347-A1 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids | NPEPPS, COASY, BCAT1 | LMNA 3682/4885L3MBTL1 1127/4885TDP1 2688/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | LMNA 3756/4885L3MBTL1 792/4885TDP1 2246/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | LMNA 3157/4885L3MBTL1 23/4885TDP1 752/4885 |
| US-12247058-B2 | Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof | FGF1, FGF2, FGF23 | LMNA 2405/4885L3MBTL1 653/4885TDP1 2159/4885 |
| US-20050170404-A1 | Linked to water soluble polyoxyethylene glycol | GHITM, HDGF, GHRHR | LMNA 3579/4885L3MBTL1 2707/4885TDP1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.